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Abstract
Sorafenib is an effective anti-angiogenic treatment for 
hepatocellular carcinoma (HCC). The assessment of 
tumor progression in patients treated with sorafenib 
is crucial to help identify potentially-resistant patients, 
avoiding unnecessary toxicities. Traditional methods 
to assess tumor progression are based on variations 
in tumor size and provide unreliable results in patients 
treated with sorafenib. New methods to assess tumor 
progression such as the modified Response Evaluation 
Criteria in Solid Tumors or European Association for 
the Study of Liver criteria are based on imaging to 
measure the vascularization and tumor volume (viable 
or necrotic). These however fail especially when the 
tumor response results in irregular development of 
necrotic tissue. Newer assessment techniques focus on 
the evaluation of tumor volume, density or perfusion. 
Perfusion computed tomography and Dynamic Contrast-
Enhanced-UltraSound can measure the vascularization 
of HCC lesions and help predict tumor response to anti-
angiogenic therapies. Mean Transit Time is a possible 
predictive biomarker to measure tumor response. 
Volumetric techniques are reliable, reproducible and 
time-efficient and can help measure minimal changes 
in viable tumor or necrotic tissue, allowing the prompt 
identification of non-responders. Volume ratio may be a 
reproducible biomarker for tumor response. Larger trials 
are needed to confirm the use of these techniques in the 
prediction of response to sorafenib.
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Core tip: The development of new treatment options for 
hepatocellular carcinoma has changed not only the way 
in which cancer is treated, but also how it is diagnosed 
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and especially the assessment of tumor response. 
The traditional radiologic methods, which are mainly 
based on the evaluation of variations in tumor size, 
are considered insufficiently sensitive and unreliable 
in determining tumor progression when targeted 
therapies like sorafenib are involved. New assessment 
tools trying to combine morphological and vascular 
functional data to obtain an accurate measurement 
of tumor characteristics such as volume, density or 
vascularization, showed positive results in assessing 
patient’s response to therapy.
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J Hepatol 2015; 7(1): 33-39  Available from: URL: http://www.
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INTRODUCTION
With an incidence doubled in the last decades, increased 
mortality rates, and important risk factors associated 
with its development, hepatocellular carcinoma (HCC) is 
considered the most common primary liver malignancy[1]. 
The management of  HCC is complex and often requires 
a multidisciplinary approach in order to select the most 
appropriate treatment and to reduce toxicity[2].
The only medical treatment approved for HCC 
is the oral multikinase inhibitor sorafenib (SO)[3,4]. 
Its mechanism of  action is based on the inhibition 
of  a number of  pro-angiogenic signaling pathways, 
that, stimulating angiogenesis, are responsible of  the 
characteristic hypervascular pattern of  HCC lesions[5]. 
The therapeutic response to SO correlates with changes 
in tumor structure, including decreased vascularization 
and increased tissue necrosis or cavitation, but it is 
not always associated with reduction in tumor size[6,7]. 
Clinical trials showed that SO is an effective treatment 
for advanced-stage HCC[8]. Moreover, the efficacy and 
safety of  the combination of  SO with other standard 
treatments for intermediate and advanced-stage HCC, 
such as Transarterial Chemo Embolization (TACE), is 
still under investigation[8-10].
Present research efforts are devoted to the refinement 
of  prognosis prediction by molecular profiling and 
enhanced clinical characterization to further improve 
therapies and, in turn, increase life expectancy of  
patients[3].
The assessment of  tumor progression during SO 
treatment is an open issue: traditional radiologic methods 
mainly based on the evaluation of  changes in tumor size 
are considered insufficiently sensitive and unreliable[11]. 
The phase Ⅲ SHARP trial[4] showed that the Response 
Evaluation Criteria in Solid Tumors (RECIST) 1.1[12] 
did not correlate with the SO-induced positive clinical 
outcome and that its ability to predict patient’s response 
was very limited[4].
In this paper, we will review the new available tools 
that showed promising results for the assessment of  
HCC patients’ response to Sorafenib treatment.
TRADITIONAL ASSESSMENT TOOLS: 
MODIFIED RECIST AND THE EUROPEAN 
ASSOCIATION FOR THE STUDY OF 
LIVER
The modified RECIST (mRECIST) was recently 
proposed by the American Association for the Study of  
Liver Diseases (AASLD) as a new assessment method 
able to overcome the main limitations of  RECIST 
criteria by including, among the evaluation criteria, the 
changes in tumor structure induced by anti-angiogenic 
treatments[13]. mRECIST assesses the vascularization of  
a lesion and the changes in tumor arterial enhancement 
through imaging techniques, such as the contrast-
enhanced spiral computed tomography (CT) or dynamic 
magnetic resonance imaging (MRI). Neo-angiogenesis is 
in fact well-enhanced both in the arterial phase of  MRI 
and in CT although MRI contrast agents provide better 
visualization[14]. However, for an appropriate evaluation, 
the AASLD guidelines recommend the assessment of  
tumor lesions also at baseline, as well as the optimization 
of  image acquisition protocols and interpretation[13]. 
The European Association for the Study of  Liver 
(EASL), in 2000, suggested a similar approach that 
included the evaluation of  changes in tumor enhancement 
through contrast-enhanced imaging also to establish 
variations in viable tumor and necrotic areas[15].
The ability of  mRECIST and EASL criteria to assess 
patients with HCC treated both with loco-regional 
therapy or systemic agents were compared with the 
traditional RECIST criteria in different studies[16-21]. 
Results showed that mRECIST and EASL criteria are 
sufficiently reliable in assessing response to loco-regional 
treatment, but some uncertainties remain whether using 
these criteria after target agents[22]. Necrotic areas after 
loco-regional therapy are usually predictable and well-
defined necrotic areas. Conversely, SO can result in an 
irregular and unpredictable development of  necrosis 
since the decreased tumor vascularization does not 
always translate in necrotic tissue[20,23]. A recent study 
however showed that EASL and mRECIST responses 
are independent predictors for overall survival in patients 
treated with the combination of  SO and TACE, and that 
this response can be evaluated early (3 mo)[21].
This scattered scenario suggests that criteria based on 
an overall visual assessment can be misleading and may 
lead to inaccurate measurements; therefore, there is a 
strong need to develop new and more reliable assessment 
tools.
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NEW ASSESSMENT TOOLS
The research effort towards the development of  new 
assessment tools for SO response grounds on the consi-
deration that, provided the high impact of  SO on tumor 
vascularity, techniques able to combine morphological and 
vascular functional data can be more effective than the 
traditional criteria[24]. In addition, EASL and AASLD 
guidelines underline that the portion of  viable tumor, 
and not the whole tumor mass, is the most important 
evaluation parameter, which depends on the blood flow 
within and vascularization of  the lesions. 
Hence, perfusion-CT (pCT) and Dynamic Contrast-
Enhanced-UltraSound (D-CEUS) are at the basis of  some 
current strategies for the evaluation of  tumor perfusion 
and tumor density[24-26], whereas other authors propose 
volumetric assessment of  tumor as possible marker of  
progression[27-29]. 
Last, several tumor biomarkers are under investigations 
as possible prognostic and predictive factors for SO 
response aimed to help identifying candidate resistant 
patients, possibly candidate with alternative treatments, 
and avoiding unnecessary toxicities.
New tools for the evaluation of tumor perfusion and 
density
pCT and D-CEUS were recently identified as possible 
practical and non-invasive radiological techniques that, 
enabling the visualization of  tissue microcirculation, 
are able to provide information related to the diagnosis, 
stratification, and prediction of  the response to treatment 
in oncologic patients[30,31]. Moreover, the sensitivity, 
rapidity, and efficacy of  these imaging techniques was 
further advanced with the introduction of  multidetector 
CT scanners and of  commercially-available software for 
data analysis[32]. Provided their ability to evaluate tissue 
vascularization, these techniques were also explored as 
possible tools to measure the efficacy of  anti-angiogenic 
therapies[31,33,34]. The studies investigating pCT and 
D-CEUS ability to measure treatment response were 
conducted both in patients treated with SO and in 
patients treated with bevacizumab. These two therapies 
are comparable in terms of  tumor response, that is 
similar with the two molecules; however, from a clinical 
viewpoint, they greatly differ in relation to HCC treatment 
as bevacizumab is not used to treat HCC patients.
Another very recent approach concerned the use 
of  the apparent diffusion coefficient (ADC), reflecting 
diffusion of  water in tissue, measured by DW-MRI that 
was already demonstrated to correlated with response to 
chemotherapy[35].
pCT parameters: pCT parameters such as blood flow 
(BF), blood volume (BV), mean transit time (MTT) and 
permeability surface area (PS) are significantly different 
in HCC lesions compared with normal liver tissue and 
correlate to the tumor stage[26,30,36]: whereas BF, BV, and 
PS were reported to be higher in advanced HCC than in 
moderately differentiated HCC tissue, MTT was lower in 
advanced HCC[30]. 
pCT was compared to RECIST and tumor density in a 
phase Ⅱ clinical trial involving 23 patients with advanced 
HCC undergoing bevacizumab for the evaluation of  the 
response to treatment[33]. Whereas no variations in tumor 
size (RECIST) and only a mild reduction in tumor density 
were observed, pCT parameters significantly correlated 
to patient’s response [progression free survival (PFS)]: 
higher MTT baseline values were directly correlated to 
better clinical outcome and 6-mo PFS[33]. Similar results 
were reported on 33 advanced HCC patients under 
bevacizumab, who showed a significant decrease in tumor 
perfusion and an increase in MTT values after treatment 
administration[31]. Also, patients in which the disease 
progressed had lower baseline MTT levels that highly 
increased after treatment when compared to those with 
partial or complete response to treatment[31].
The results obtained in patients treated with beva-
cizumab and evaluated through pCT were recently 
confirmed in a series of  10 patients treated with SO[26]: at 
3 mo after the initiation of  SO treatment, patients showed 
a progressive decrease of  BF, BV, and PS and a significant 
increase of  MTT compared to baseline values[26]. All 
together, these results support the hypothesis that pCT, 
and, more specifically, MTT, can be a valuable candidate 
predictive biomarker for SO response in HCC patients[26].
D-CEUS: D-CEUS was used to study tumor perfusion 
and dynamic changes in tumor vascularity in patients 
under bevacizumab treatment[34]. Changes were detected as 
early as 3 d after bevacizumab administration, suggesting 
that they could be used to predict tumor response and, 
in turn, measure the effectiveness of  anti-angiogenic 
therapies[34]. In patients treated with SO, positive tumor 
response and longer survival rates were associated to 
increased or unchanged time to peak intensity (Tp) and 
MTT values, as well as decreased area under the curve 
(AUC)[37]. Moreover, AUC, Tp and slope of  wash in (Pw) 
positively correlated to PFS, thus suggesting that D-CEUS 
is able to provide a measure of  the efficacy of  anti-
angiogenic therapy and a reliable help in the selection of  
patients who could benefit from SO treatment[37].
pCT and D-CEUS as measure of  tumor response 
were recently compared in 11 HCC patients treated with 
SO[24]. Despite decreasing consistently after treatment, 
pCT parameters were not able to discriminate between 
responders and non-responders. Conversely, a decrease 
of  more than 40% in the AUC measured through 
D-CEUS after 1-mo treatment was found as a strong 
predictor of  lack of  progression at 2-mo, thus enabling 
the differentiation between patients who responded to 
therapy and those who did not[24]. D-CEUS was then 
suggested as possible marker of  SO response, although 
the results of  pCT analysis may have been biased by the 
small number of  patients[24]. As a further application of  
CEUS, in a murine HCC mode CEUS obtained using 
vascular endothelial growth factor receptor-2 (VEGFR-2) 
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including traditional radiological criteria (RECIST1.1., 
EASL and mRECIST). The results showed that none 
of  the three radiological criteria showed a significant 
correlation with patients’ survival and that the only 
parameter associated with survival was volume rate: an 
increase ≥ 10% in tumor volume after 2-mo was found 
as negative predictive factor for survival. The study also 
confirmed[27-29] the reproducibility of  measurements, with 
high degree of  inter- and intra-observer agreement, thus 
suggesting that, whereas traditional criteria to measure 
tumor response are not reliable in the case of  SO admini-
stration, volume assessment seem to be an early and 
reproducible biomarker for tumor response[22]. 
Despite these promising results, larger trials are 
needed to confirm data on volumetric assessment as tool 
for measuring tumor volume in HCC patients, especially 
if  treated with SO, and to investigate the correlation 
between measurement of  changes in tumor volume and 
response to therapy. 
The prognostic and predictive values of tumor 
biomarkers
Several studies are investigating new and more accurate 
predictive and prognostic factors for response to SO. 
They include the evaluations of  alpha-fetoprotein (AFP) 
levels[26,39-44], genotype and phenotype features, such as 
VEGF family single nucleotide polymorphisms (SNPs)[45,46], 
and the differential blood cell counts, particularly the 
neutrophil-lymphocyte ratio (NLR)[47-49].
AFP is a glycoprotein secreted in approximately 70% of  
HCC, and it is considered as an useful biomarker for HCC 
diagnosis[39,40]. The mechanism of  action could be related 
to SNPs in human AFP promoter that lead to uncontrolled 
transcriptional activities[50]. It has also been suggested that 
AFP could act possible predictor of  response to anti-
cancer and anti-angiogenic treatment[39-41,43]. The role of  
AFP in measuring the response to SO is however debated 
and deserves further considerations[43,51] since authors 
reported heterogeneous results[22,40-44]. 
Some studies suggest that, in patients treated with 
SO, AFP decrease is an independent predictors of  good 
response to sorafenib[41,44] and that the early increase in 
AFP is associated with poor survival[40]. In a nationwide 
retrospective study, high AFP levels at baseline were 
consistently shown to be prognostic for a shorter survival, 
and SO responders showed a significant decline in AFP 
during the first month treatment[43]. Conversely, in the 
study evaluating different measures of  tumor progression 
in 10 patients receiving SO, authors reported an inverse 
correlation between baseline MTT values, that were 
predictive of  SO response, and changes in AFP after 3 
mo, but changes in AFP levels were not associated with 
response rate[26]. 
Gene expression is believed as one of  the main 
responsible of  responsiveness to treatments in HCC 
patients[52]. The lack of  response to SO in HCC patients 
was shown to be correlated to a mesenchymal-like 
phenotype and expression of  CD44, linked to activation 
targeted microbubbles was demonstrated to be effective 
in measuring SO response: the differential targeted 
enhancement due to bound microbubbles in the tumor 
significantly decreased in the mice treated with SO, and 
was able to discriminate the non-responder group from 
the responders[38].
Last, the ADC obtained from DW-MRI was applied in 
mice to investigate its ability as an indicator of  response 
to SO in HCC. Lower ADC values and a stronger 
progressive ADC decrease were observed in mice treated 
with SO than in the control group, thus prompting 
further research on this technique for the evaluation of  
SO response[35]. 
New tools for volumetric assessment
Volumetric techniques are regarded to as possible alter-
native methods to measure the whole tumor volume 
instead of  the traditional approach of  RECIST and EASL 
that, being based on the evaluation of  a representative 
axial slice of  the tumor, do not take into account its entire 
volume[22,27-29]. In fact, SO and other anti-angiogenic 
treatments induce the development of  an often irregular 
and not-homogeneous necrotic area, so that the area 
selected for evaluation may not be representative of  the 
whole tumor. Volumetric techniques take into consideration 
the entire tumor load and are able to detect even minimal 
changes in viable tumor or necrotic tissue, thus allowing the 
prompt identification of  non-responders[22]. In addition, 
the introduction of  automatic and semi-automatic software 
for image segmentation, have provided faster, more reliable 
and user-friendly tools for volume measurement, leading 
to rapid spread of  these techniques[27-29]. 
In 17 HCC patients treated with TACE, semi-automatic 
3D volume segmentation technique based on a voxel-by-
voxel analysis for measuring tumor volume and enhancement 
pattern was reported to be reproducible and time-effective, 
and to provide a more accurate estimation of  tumor burden 
than 2D techniques[28]. Similarly, HCC necrosis measured 
by volumetric assay was more reproducible than that obtain 
with the 2D measurement in 29 HCC patients, treated with 
yttrium-90 radioembolization[29]. According to the results 
of  this study, the mean values of  necrosis obtained with the 
two methods significantly differed[29]. 
In small retrospective involving 23 HCC or liver 
metastasis patients undergoing radioembolization, volumetric 
assessment demonstrated good intra/intra-observer 
reproducibility[27]. Both whole tumor and necrotic areas 
were measured providing good accuracy and reliability. 
Also, the authors observed a significant difference in 
survival time, in a Kaplan-Meier analysis, between patients 
whose change in necrotic area was ≥ 10% compared with 
those with necrosis ≤ 10%, thus suggesting a possible 
correlation between survival rates and tumor necrosis 
measured through this technique[27]. 
To our knowledge, response to SO using tumor 
volume assessment was investigated only in one 
prospective study involving 22 HCC patients in which the 
response to therapy was evaluated by multiple criteria[22], 
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of  the transforming growth factor-β pathway[53] and the 
combined HTATIP2 expression and microvessel density 
was found to be a predictor of  SO response[54]. Some 
studies also highlighted the role of  VEGF[45], suggesting 
that patients responsiveness to SO may be well defined 
through the analysis of  VEGF and VEGFR SNPs[46].  
NLR was investigated as prognostic factor both in 
patients receiving SO[47,48] and in those not receiving 
SO[49]. In HCC patients not treated with SO, low NLR 
was associated with higher survival[49]. Similarly, high 
periprocedural NLR was associated with poor survival 
in patients with unresectable HCC on SO treatment[47,48] 
even if  these results deserve further consideration[55]. 
CONCLUSION
The traditional assessment criteria for the evaluation 
of  SO response in HCC treatments demonstrated to 
be inappropriate to reliably predict the clinical response 
to treatment. Despite adjustments resulting in the 
development of  modified criteria such as mRECIST 
and EASL, these tools still show important limitations, 
especially when the tumor response results in irregular 
development of  necrotic tissue. The introduction of  new 
and efficient biomarkers to measure patients’ response 
to SO could enable the early assessment of  patients’ 
response, reducing unnecessary costs and adverse events, 
and improving final patients’ outcome.
New tools for the evaluation of  tumor progression 
were developed and are under investigation. They focus on 
providing a precise estimate of  the changes in viable tumor 
volume, through the measurement of  tumor perfusion 
or through volumetric assessment. More specifically, the 
perfusion parameter MTT and the volume ratio were 
identified as predictive biomarkers of  therapeutic response.
Despite these promising positive results of  both these 
techniques, available data are still scant and prompt new 
larger systematic validation studies. Although there is 
no gold standard for response evaluation in HCC, these 
validation studies should be based on the suggestions 
reported in current guidelines. As already done in the 
available studies, the validation of  these new approaches 
should rely on the comparison between their results and 
those obtained through standard assessment methods 
(EASL, mRECIST), while bearing in mind the limitations 
of  each approach.
Once the necessary technological advancements will 
be completed, it is expected the introduction of  these 
new assessment methods in the clinical practice, enabling 
the prompt identification of  subjects not responding 
to a specific therapy, resulting in a reduction in adverse 
events and unnecessary costs and leading to a more rapid 
identification of  the best treatment approach for each 
subject.
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